Obigen Pharma will unblind its Phase 3 Botox trial in November, moving faster than the original timeline. The Taiwan-based company is also planning a year-end capital raise targeting NT$400 million-plus to fund the final stretch toward regulatory submission.
Injectables
Obigen Unblinding Botox Phase 3 Trial Early
Taiwan biotech accelerates timeline for alternative toxin candidate ahead of year-end funding push.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Obigen accelerates Phase 3 unblind to November ahead of NT$400M+ year-end raise.
This matters because the neuromodulator market remains dominated by AbbVie's Botox and Galderma's Dysport, with Revance's Daxxify still climbing share post-launch. A new entrant with Phase 3 data and funding secured signals real competitive pressure ahead. Obigen's accelerated unblind suggests confidence in efficacy and safety readouts—or urgency to de-risk the program before investor appetite shifts.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.